Repare Therapeutics Inc. (RPTX)
Automate Your Wheel Strategy on RPTX
With Tiblio's Option Bot, you can configure your own wheel strategy including RPTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RPTX
- Rev/Share 0.2763
- Book/Share 2.6795
- PB 0.9479
- Debt/Equity 0.003
- CurrentRatio 10.7079
- ROIC -0.6503
- MktCap 109165708.0
- FreeCF/Share -1.6327
- PFCF -1.5562
- PE -1.5115
- Debt/Assets 0.0027
- DivYield 0
- ROE -0.5756
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Published: December 24, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class.
Read More
Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights
Read More
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Repare Therapeutics Inc. (NASDAQ: RPTX ) related to its sale to XenoTherapeutics, Inc. Upon closing of the proposed transaction, it is estimated that each Repare shareholder will receive a cash payment of $1.82 per share, plus one …
Read More
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.82 per share a year ago.
Read More
About Repare Therapeutics Inc. (RPTX)
- IPO Date 2020-06-19
- Website https://www.reparerx.com
- Industry Biotechnology
- CEO Steve Forte
- Employees 129